MedPath

FDA Approves Geron's RYTELO™ (imetelstat) for Lower-Risk MDS

  • The FDA has approved Geron's RYTELO™ (imetelstat) for adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia and are unresponsive to or ineligible for erythropoiesis-stimulating agents (ESA).
  • The approval was based on the IMerge Phase 3 trial, where RYTELO™ significantly increased red blood cell transfusion independence compared to placebo, with nearly 40% achieving independence for at least eight weeks.
  • RYTELO™ is the first telomerase inhibitor approved by the FDA, representing a novel treatment class that targets telomerase, which is overexpressed in malignant bone marrow cells in LR-MDS, aiming to reduce cancer cell proliferation.
  • Administered intravenously every four weeks, RYTELO™ offers a new option for managing LR-MDS, with common side effects including manageable thrombocytopenia and neutropenia, and is supported by the REACH4RYTELO™ patient program.
The U.S. Food and Drug Administration (FDA) has granted approval to Geron Corporation's RYTELO™ (imetelstat) for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who are transfusion-dependent and either unresponsive to or ineligible for erythropoiesis-stimulating agents (ESA). This decision marks a significant advancement in the treatment landscape for LR-MDS, a form of blood cancer that often leads to chronic red blood cell transfusions and reduced quality of life.
The approval is rooted in the positive outcomes of the IMerge Phase 3 clinical trial. The trial demonstrated that RYTELO™ significantly improved transfusion independence rates compared to placebo. Specifically, nearly 40% of patients treated with RYTELO™ achieved red blood cell transfusion independence for at least eight consecutive weeks, while 28% achieved independence for at least 24 weeks. In contrast, only 15% and 3.3% of patients in the placebo group achieved transfusion independence for eight and 24 weeks, respectively.
LR-MDS is characterized by ineffective blood cell production in the bone marrow, leading to anemia and often necessitating regular red blood cell transfusions. These transfusions can lead to iron overload and other complications, further diminishing patients' health and survival rates. The current treatment landscape for LR-MDS includes ESAs, but many patients either do not respond or become resistant to these agents, leaving a significant unmet medical need.

Mechanism of Action and Administration

RYTELO™ (imetelstat) is a first-in-class telomerase inhibitor. Telomerase, an enzyme that maintains the length of telomeres, is often overexpressed in malignant bone marrow cells in LR-MDS. By inhibiting telomerase, imetelstat aims to reduce the proliferation and survival of these cancerous cells. The treatment is administered as an intravenous infusion every four weeks, aligning with routine blood count monitoring for patients.

Safety and Efficacy Profile

The most common severe side effects observed in the IMerge trial were thrombocytopenia and neutropenia. These hematological adverse events were generally manageable and resolved relatively quickly. The safety profile is considered acceptable given the significant clinical benefit observed in terms of transfusion independence.

Patient Support Program

Geron offers the REACH4RYTELO™ Patient Support Program to assist eligible patients in accessing the treatment. This program aims to provide comprehensive support to patients throughout their treatment journey.

Future Prospects

Geron is also progressing with a Phase 3 trial for imetelstat in myelofibrosis, with key analyses expected in the coming years. The company is planning to expand its workforce to support the commercial launch of RYTELO™. Furthermore, Geron aims for imetelstat patent exclusivity extension until 2037.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Celgene’s Multiple Myeloma Orphan Drug Gets FDA Approval

The FDA has approved Celgene's Pomalyst, a treatment for multiple myeloma, under its accelerated approval program. Pomalyst is intended for patients who have not responded to other treatments, offering a new option for those with this rare condition.

CHMP Recommends Approval of Geron's Rytelo for Lower-Risk Myelodysplastic Syndromes

The Committee for Medicinal Products for Human Use (CHMP) has recommended Rytelo (imetelstat) for approval in the EU for transfusion-dependent anemia due to lower-risk myelodysplastic syndromes.

FDA Grants Fast Track Designation to Rigel's R289 for Lower-Risk Myelodysplastic Syndrome

The FDA has granted Fast Track designation to R289, Rigel Pharmaceuticals' IRAK1/4 inhibitor, for previously treated transfusion-dependent lower-risk myelodysplastic syndrome (MDS).

FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia

The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.

Johnson & Johnson Seeks FDA Approval for Daratumumab in High-Risk Smoldering Multiple Myeloma

Johnson & Johnson has submitted an application to the FDA for daratumumab as a subcutaneous monotherapy for high-risk smoldering multiple myeloma (SMM).

CytoDyn Receives FDA Clearance for Phase II Oncology Trial of Leronlimab in Colorectal Cancer

CytoDyn has received FDA clearance to begin a Phase II oncology trial evaluating leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.

FDA Approves RYTELO™ (imetelstat) for Transfusion-Dependent Anemia in Low-Risk MDS

The FDA has approved RYTELO™ (imetelstat) for adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.

Cresilon Receives FDA Clearance for TRAUMAGEL

Cresilon Inc. has received FDA 510(k) clearance for TRAUMAGEL, a plant-based hemostatic gel designed to control moderate to severe bleeding in seconds. This innovative product aims to save lives by quickly stopping life-threatening bleeding at the point of care.

FDA Approves Darzalex Faspro Quadruplet Regimen for Transplant-Eligible Multiple Myeloma

The FDA has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.

FDA Approves RYTELO™ (imetelstat) for Lower-Risk MDS with Transfusion-Dependent Anemia

The U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) who suffer from transfusion-dependent anemia. This approval is based on the results from the IMerge Phase 3 clinical trial, which demonstrated significant benefits in terms of red blood cell transfusion independence and increases in hemoglobin levels among patients.

Reference News

[1]
FDA approves Geron's treatment for lower-risk MDS blood cancer By Investing.com
investing.com · Jun 7, 2024

Geron Corporation's RYTELO™ (imetelstat) received FDA approval for treating transfusion-dependent anemia in lower-risk m...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy